Overview

OH2 Injection in Melanoma

Status:
Recruiting

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of OH2 injection in patients with unresectable or metastatic melanoma who have failed at least second-line standard therapy, using investigator-selected salvage chemotherapy or best supportive care (BSC) as controls.

Phase:

Phase 3

Details

Lead Sponsor:

Binhui Biopharmaceutical Co., Ltd.